Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

Inclusion Criteria: * Patients attaining ≥grade 2(moderate) in the investigator's rating of the severity of glabella line at maximum frown * Men and women aged between 20 and 65 * Patients who him/herself or him/her legal representatives voluntarily signed the informed consent * Patients who can comply with the study procedures and visit schedule Exclusion Criteria: * Patients with general neuromuscular synaptic disorder(e.g. Myasthenia gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis) * Patients who have bleeding tendency or taking anti-coagulant * Patients suffering from acute diseases * Patients who have been injected with botulinum toxin within past 3 months before the injection * Patients with allergy or hypersensitivity to the investigational products or their components * Patients who are pregnant or lactating or found to be pregnant through the urine or serum test or disagreed to avoid pregnancy during 16 weeks study period * Patients who have been given any of the following drugs within previous 4 weeks at screening: Muscle relaxants, benzodiazepine, aminoglycoside antibiotics, other antibiotics, and anticholinergic drugs. * Patients with the history of facial nerve paralysis or the symptoms of eyelid ptosis * Patients with skin damage or infection at the injection site. * Patients who scheduled a double eyelid operation during the clinical trial. * Patients who have received or have a plan to receive other procedures, which may affect glabella and forehead lines within 6 months * Patients whose glabella lines cannot be spread apart even with physical methods like using hands. * Patients who are participating in other clinical trials or have participated in other clinical trials within 30 days of the screening date. * Patients who are unable to communicate or follow the instructions * Patients who are not eligible for this study at the discretion of the investigator